Amphista Therapeutics is a pioneering brand that is dedicated to developing novel medicines through next-generation protein degradation. With a strong focus on targeted protein degradation (TPD), Amphista is revolutionizing the field of therapeutic innovation to create therapies with significantly improved efficacy. At the core of their success lies their proprietary Eclipsys™ Drug Development platform, which is expanding the therapeutic applications of TPD.

This cutting-edge platform allows Amphista to identify and advance novel approaches, unlocking the full potential of targeted protein degradation. Amphista Therapeutics offers an exciting and fast-moving working environment, providing ample opportunities for growth and development. By joining their team, you can make a positive difference in the lives of patients.

Stay up-to-date with the latest news from Amphista, as they continue to make strides in the industry. Recently, they appointed Dr. Giles Brown as Senior Vice President of Chemistry and achieved their first discovery milestone in collaboration with Bristol Myers Squibb.

Unlock the full potential of targeted protein degradation with Amphista Therapeutics and contribute to the development of more effective medicines for patients